Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2008-09-10 18:00:08

By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives. Anna Wolfenden's open letter to Ms Hart calls for a swift decision to be made about the availability of drugs such as Sunitinib that are widely available for patients with kidney cancer in the United States and other countries but have failed to secure the recommendation of NHS bodies in...

2008-09-10 12:00:51

BRIDGEWATER, N.J., Sept. 10 /PRNewswire/ -- Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, today published a special issue of Adis PharmacoEconomics devoted to helping drug makers better understand the requirements behind the so-called "fourth hurdle" -- demonstrating a drug's reasonable cost effectiveness. The issue focuses on the...

2008-09-09 21:00:20

Professor Karol Sikora said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.He calculated they could cost the NHS 50bn around half the current budget, which tops 100bn.The professor, who is director of Cancer Partners UK, a private provider of cancer services that works with the NHS, came up with the figures for Sky News.He said: "50bn is the equivalent to raising tax by 15p for...

2008-09-09 18:00:32

By Jane Kirby THE high cost of cancer drugs could lead the NHS into "meltdown", a leading expert said today. Professor Karol Sikor a said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years. He calculated they could cost the NHS pounds 50bn - around half the current budget, which tops pounds 100bn. The professor, who is director of Cancer Partners UK, a private provider of...

2008-09-08 15:00:00

By Helen Puttick IT is, perhaps, an unusual move; from an organisation which fought for patients to one that often faces accusations of acting against their interests. But Andy Powrie-Smith insists his surprise appointment as director of the Association of the British Pharmaceutical Industry is simply working for patients in a different way. The new director was, when the announcement was made, the head of a charity, the British Lung Foundation Scotland - which fights for patients...

2008-09-05 00:00:26

By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision. If Colin Ross continues to be denied the drug, Revlimid, he will die within a few months, experts say. His lawyers told the High Court yesterday that he was the victim of a postcode lottery. Mr Ross, 55, said his doctors had requested funding for up to four courses of Revlimid at 5,000 a...

2008-09-04 12:00:32

With the cost of healthcare provision spiraling, governments and payers across the seven major markets are applying cost-cutting measures, putting even greater pressure on pharmaceutical companies. In the UK, the National Institute of Clinical Excellence recently rejected four new kidney cancer therapies on the basis of cost effectiveness, effectively denying patients access to these novel drugs. It is not just the credit crunch that is putting pharmaceutical companies under pressure....

2008-09-02 00:00:28

According to charity Infertility Network UK, North Staffordshire PCT is one of just three health authorities across the country which has suspended funding for IVF. The charity says 92 PCTs fund one cycle of treatment, 32 fund two and nine fund three cycles. The National Institute for Health and Clinical Excellence (NICE) recommends women aged between 23 and 39 receive three free cycles of fertility treatment on the NHS. Government guidance states PCTs should provide a minimum of one...

2008-09-01 12:00:20

DR McGONAGLE'S put-down of NICE (Letters, August 28) as the "National Institute of Complete Embarrassment" does a disservice. NICE has produced final guidance for the drug Lucentis, now accepted for use throughout the UK. It slows age-related macular degeneration (AMD) which gradually destroys central vision, making reading or driving difficult or impossible. This is clearly not a trivial problem - but neither are the processes required to ensure fairness when deriving priorities for use...

2008-08-28 06:01:10

The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration. The announcement is said to be an important development for patients because the National Institute for Health and Clinical Excellence (NICE) determines access to medicines in England and Wales based on agreed standards of cost-effectiveness. The final guidance comes at the end of a rigorous review...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related